501-3292
Production Way, Burnaby, B.C., V5A 4R4
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix
Technologies Provides
Update
on
THC Breathalyzer
Beta-Testing
Cannabix
is developing
Marijuana
Breathalyzer
devices to
give law enforcement and employers
a
tool to
enhance
public safety
Vancouver, British
Columbia -- June
1,
2021 -- InvestorsHub
NewsWire -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the
"Company" or
"Cannabix")
developer
of the Cannabix Marijuana Breathalyzer devices
for law
enforcement and the workplace, reports that it expects to ship
its THC Breath Analyzer
("THCBA")
to a
clinic in the Northwestern,
U.S. for beta
testing in the coming
days. The collaborating
clinic has a robust drug testing operation and is one of the top
drug testing providers to employers within its respective
state. This new beta-testing
site will be an addition to beta-testing launched
earlier in the year. The Company is also
reviewing new opportunities for testing
in the
province of Ontario.
The Company has
received early positive qualitative
feedback
of its THCBA device with regards to
human
factors usage
of the
device. Beta-testing has been ongoing with Alipour Medical
Centre, an
occupational health
care provider located in Newport Beach California.
Dr. Nima Alipour,
Chief Medical Officer of AMC, the Occupational Medicine Division of
Hybrid Health Systems, stated, "My team and I have found the THCBA
easy to use and have been impressed with its intuitive
administrative and user functionality with the capacity to complete
a breath test within 5 minutes per subject, we think this will be
important for employers who conduct drug testing in various work
environments and require quick results. We have provided
feedback on breath sample collection, connectivity, battery
management, handling and sanitation of the device. As
occupational health practitioners based in California, we
understand the challenges that employers are facing in providing
relevant drug testing for both
new and existing employees. This
is an exciting new tool that can move drug testing for cannabis
forward from where it is now, to providing actionable insights on
impairment vs. legal and prescribed use."
Cannabix is
seeking and reviewing
additional
beta-testing sites. Beta-testing of
the THCBA
prototype
is
focused
on improving user and
administrator experience, identifying
cross-reactivity
of
other
substances within a
semi-controlled
study
population and to
further
train the device's machine
learning database and sensitivity
profile. The THCBA is a drug
screening device for employers and other markets who are seeking a
way to quickly, easily and non-invasively test for recent use of
?9-tetrahydrocannabinol
("THC")
- the psychoactive component of marijuana that causes
impairment.
The Company
also
reports
that
it
has
expanded its facility in Burnaby, BC to among other things,
accommodate assembly of more devices and bring on
additional
staff.
About Cannabix
Technologies Inc.
Cannabix Technologies
Inc. is a developer of marijuana breathalyzer technologies for law
enforcement and the workplace. Cannabix is working to develop
drug-screening devices that will detect THC - the psychoactive
component of marijuana that causes impairment using breath samples.
Breath testing for THC would allow employers and law
enforcement to identify
recent marijuana use that better
aligns with impairment.
We seek Safe
Harbor.
On
behalf of the Board of Directors
"Rav
Mlait"
CEO
Cannabix Technologies
Inc.
For
further information, contact the Company at
info@cannabixtechnologies.com
The
CSE has not reviewed and does not accept responsibility for the
adequacy or accuracy of this release.
Cautionary Statement
Regarding Forward-Looking Statements
This press release
contains forward-looking information that involves various risks
and uncertainties regarding future events. Such forward-looking
information can include without limitation statements based on
current expectations involving a number of risks and uncertainties
and are not guarantees of future performance of the Company, such
as final development of a commercial or prototype product(s),
successful trial or pilot of company technologies, no assurance
that commercial sales of any kind actually materialize; no
assurance the Company will have sufficient funds to complete
product development. There are numerous risks and uncertainties
that could cause actual results and the Company's plans and
objectives to differ materially from those expressed in the
forward-looking information, including: (i) adverse market
conditions; (ii) risks regarding protection of proprietary
technology; (iii) the ability of the Company to complete
financings; (iv) the ability of the Company to develop and market
its future product; and (v) risks regarding government regulation,
managing and maintaining growth, the effect of adverse publicity,
litigation, competition and other factors which may be identified
from time to time in the Company's public announcements and
filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing "patent pending" technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.
